Table 2.
HPV status and outcomes for 2282 women included in analysis
| HPV status | All women | High risk women* | Low risk women† | |||||
|---|---|---|---|---|---|---|---|---|
| No of women | No (%) with CIN II+ | No of women | No (%) with CIN II+ | No of women | No (%) with CIN II+ | |||
| Repeatedly positive for carcinogenic HPV (Pos/Pos): | ||||||||
| Total | 260 | 46 (17.7) | 246 | 44 (17.9) | 14 | 2 (14.3) | ||
| HPV 16 persistence | 55 | 20 (36.4) | 52 | 19 (36.5) | 3 | 1 (33.3) | ||
| HPV 18 persistence | 18 | 5 (27.8) | 18 | 5 (27.8) | 0 | 0 | ||
| Type specific persistence | 136 | 21 (15.4) | 126 | 20 (15.9) | 10 | 1 (10.0) | ||
| Non-specific persistence | 51 | 0 (0.0) | 50 | 0 (0.0) | 1 | 0 (0.0) | ||
| Acquisition (Neg/Pos) | 125 | 6 (4.8) | 111 | 5 (4.5) | 14 | 1 (7.1) | ||
| Clearance (Pos/Neg) | 282 | 5 (1.8) | 263 | 4 (1.5) | 19 | 1 (5.3) | ||
| Neg/Neg | 1615 | 13 (0.8) | 1192 | 11 (0.9) | 423 | 2 (0.5) | ||
| Total | 2282 | 70 (3.1) | 1812 | 64 (3.5) | 470 | 6 (1.3) | ||
*Screen positive or had risk factors (such as five or more lifetime sexual partners) for HPV or cervical neoplasia.
†Screen negative and did not have above risk factors.